Welcome to the SWYAPC website
Updates following the June Area Prescribing Committee Meeting
Red, Amber, Green Classifications:
Valproate – Agreement to classify as Green with Specialist Initiation for all indications
Sucralfate – Agreement to classify as RED for All indications
Chloral Hydrate – Agreement to classify as RED for Insomnia (Short term use)
Shared Care Guidelines:
Mercaptopurine – Final Version Approved
Lithium – Final Version Approved
Probiotics (no longer required in light of the new OTC Guidance) – added to the website as BLACK except VSL#3® which is ‘GSI’ for ACBS criteria i.e. for the maintenance of remission of ileo-anal pouchitis
Brimondine – Approved – To be added to the SWYAPC Website for 4 weeks for public opportunity to comment
Hyaluronic Acid – Approved – To be added to the SWYAPC Website for 4 weeks for public opportunity to comment
The ratified minutes from the April meeting have been added to the business section of the website for information.
South West Yorkshire Area Prescribing Committee – Interim Commissioning Position – Flash Glucose Monitoring Systems – Updated March 2018
The expected cost of the Flash Glucose Monitoring Systems to the NHS is over £900 per patient per year of continuous use compared with £360 – £650 per patient per year for finger pricking (based on testing 4-8 times per day). Therefore, it is currently unaffordable and unsustainable to make it available for all people with diabetes.
Work is ongoing between the six CCGs within the South West Yorkshire Area Prescribing Committee (Bradford City and Districts CCGs, Calderdale CCG, Greater Huddersfield CCG, North Kirklees CCG, Wakefield CCGs) and diabetes specialists to agree which groups of patients would gain most health benefit from using Flash Glucose Monitoring Systems, whilst keeping it affordable for the NHS.
There is also a need to consider our neighbouring heath economies to ensure consistency of care across a wider footprint, and therefore we have to take account of how neighbouring CCGs and health economies are managing this device.
The current situation re: Flash Glucose Monitoring Systems is that they are not routinely commissioned, and any requests for use need to go through the IFR process where the patient exhibits exceptionality. Patients currently using this system in the meantime should continue to self-fund; GPs should not initiate any prescriptions for Flash Glucose Monitoring Systems.
Any change to this position will be communicated to GPs as soon as an agreement is reached, and the website will be updated to reflect this.
We have put together a list of some frequently asked questions which you can find here.
Following the publication of the above NHSE guidance to CCGs; the SWYAPC CCGs intend to commission in line with the guidance and align the Commissioning Statements.
The SWYAPC have also produced a letter to inform Community Pharmacies in Bradford, Calderdale, Kirklees and Wakefield of the local plans regarding the NHSE guidance.